發(fā)布時(shí)間：2019-07-09 13:41

【摘要】：目的:榛花消腎安膠囊對(duì)糖尿病腎病患者血清C-反應(yīng)蛋白(hs-CRP)、腫瘤壞死因子-α(TNF-α)和尿單核細(xì)胞趨化蛋白-1(MCP-1)水平的影響。方法:將2014年5月—2016年5月本院收治的96例糖尿病腎病患者按其臨床治療方法分成A組、B組和C組,每組32例,A組患者予降糖、控制飲食、降低氧化應(yīng)激等常規(guī)基礎(chǔ)治療上予以西藥纈沙坦膠囊口服治療,B組患者在常規(guī)治療基礎(chǔ)上予以中成藥榛花消腎安膠囊口服治療,C組患者在B組基礎(chǔ)上聯(lián)合加用西藥纈沙坦膠囊口服治療,比較3組患者的臨床療效及臨床炎癥相關(guān)指標(biāo)水平的變化。結(jié)果:(1)3組患者治療前其CRP、IL-6、TNF-α和尿MCP-1水平均無(wú)明顯差異(P0.05),治療后3組患者CRP、IL-6、TNF-α和尿MCP-1水平較治療前均降低,且B組和C組降低程度較A組明顯,C組較B組降低更甚,比較間均具有統(tǒng)計(jì)學(xué)意義(P0.05);(2)治療結(jié)束后,B組(81.25%)和C組臨床總有效率(93.02%)明顯高于A組(62.50%),且C組(96.88%)與B組(81.25%)臨床總有效率比較具有統(tǒng)計(jì)學(xué)意義(P0.05);(3)3組間不良反應(yīng)發(fā)生率比較無(wú)統(tǒng)計(jì)學(xué)意義(P0.05),且無(wú)明顯嚴(yán)重不良反應(yīng)事件發(fā)生。結(jié)論:榛花消腎安膠囊可明顯降低DN患者血清hs-CRP、TNF-α和尿MCP-1水平,具有良好的臨床療效及安全性。
[Abstract]:Aim: to study the effect of hazelnut Xiaoshen an capsule on serum C-reactive protein (hs-CRP), tumor necrosis factor-偽 (TNF- 偽) and urinary monocyte chemoattractant protein-1 (MCP-1) in patients with diabetic nephropathy. Methods: from May 2014 to May 2016, 96 patients with diabetic nephropathy were divided into three groups: group A (n = 32), group B (n = 32) and group C (n = 32). Group A was treated with valsartan capsule on the basis of hypoglycemic, diet control and oxidative stress reduction, and group B was treated with hazelnut Xiaoshen capsule, a proprietary Chinese medicine, on the basis of routine treatment. The patients in group C were treated with western medicine valsartan capsule on the basis of group B, and the clinical efficacy and the level of clinical inflammation related indexes were compared among the three groups. Results: (1) there was no significant difference in CRP,IL-6,TNF- 偽 and urine MCP-1 between the three groups before treatment (P 0.05). After treatment, the levels of CRP,IL-6,TNF- 偽 and urine MCP-1 in the three groups were lower than those before treatment, and the decrease in group B and C was significantly lower than that in group A, and the decrease in group C was significantly lower than that in group B (P 0.05). (2) after treatment, the total clinical effective rate of group B (81.5%) and group C (93.02%) was significantly higher than that of group A (62.50%), and the total clinical effective rate of group C (96.88%) was significantly higher than that of group B (8125%) (P 0.05); (3), and there was no significant difference in the incidence of adverse reactions between group C (96.88%) and group B (P 0.05). Conclusion: Hazelnut Hua Xiaoshen an capsule can significantly reduce the levels of serum hs-CRP,TNF- 偽 and urinary MCP-1 in patients with DN, and has good clinical efficacy and safety.
【作者單位】： 長(zhǎng)春中醫(yī)藥大學(xué);吉林省中醫(yī)院內(nèi)分泌科;長(zhǎng)春中醫(yī)藥大學(xué)附屬醫(yī)院骨傷康復(fù)科;
【基金】：吉林省科技發(fā)展計(jì)劃項(xiàng)目(20150204090SF)
【分類號(hào)】：R259

【相似文獻(xiàn)】

相關(guān)期刊論文 前4條

1 鄭抗美,劉金鳳,任秀明,俎銀德;腎安膠囊改善慢性腎功能衰竭患者消化道癥狀效果觀察[J];山東醫(yī)藥;2005年08期

2 張春和;李焱風(fēng);楊毅堅(jiān);張富剛;陳天波;;腎安膠囊配合中藥治療濕熱蘊(yùn)結(jié)型慢性前列腺炎80例療效觀察[J];云南中醫(yī)中藥雜志;2008年08期

3 胡寶峰,黃明,任小強(qiáng),李秋英,裴俊青,陸中新;腎安膠囊治療慢性腎衰竭42例臨床研究[J];中國(guó)中西醫(yī)結(jié)合腎病雜志;2001年09期

4 ;[J];;年期

相關(guān)碩士學(xué)位論文 前4條

1 任健鋒;復(fù)方榛花消腎安膠囊對(duì)實(shí)驗(yàn)性糖尿病腎病大鼠足細(xì)胞Podocalyxin的實(shí)驗(yàn)研究[D];長(zhǎng)春中醫(yī)藥大學(xué);2015年

2 高穎源;復(fù)方榛花消腎安膠囊對(duì)實(shí)驗(yàn)性糖尿病腎病大鼠足細(xì)胞Podocin的實(shí)驗(yàn)研究[D];長(zhǎng)春中醫(yī)藥大學(xué);2015年

3 許靜;消渴腎安膠囊治療糖尿病腎病肝腎陰虛兼血瘀證的臨床研究[D];長(zhǎng)春中醫(yī)藥大學(xué);2011年

4 方慧南;消渴腎安膠囊干預(yù)早期糖尿病腎病尿微量白蛋白及氧化應(yīng)激的臨床研究[D];長(zhǎng)春中醫(yī)藥大學(xué);2013年

，

本文編號(hào)：2512183